MCID: OPT003
MIFTS: 54

Opiate Dependence

Categories: Mental diseases

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Name: Opiate Dependence 12 14
Opioid-Related Disorders 41 69
Opioid Dependence 72 51
Opioid Type Dependence 12
Opiate Addiction 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2559
ICD10 32 F11.2
ICD9CM 34 304.0 304.00
MeSH 41 D009293

Summaries for Opiate Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance.

MalaCards based summary : Opiate Dependence, also known as opioid-related disorders, is related to opioid dependence 1 and morphine dependence. An important gene associated with Opiate Dependence is ODS1 (Opioid Dependence, Susceptibility To, 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Buprenorphine and Heroin have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and skin, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 72 Opioid use disorder is a medical condition characterized by a problematic pattern of opioid use that... more...

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Related Disease Score Top Affiliating Genes
1 opioid dependence 1 33.7 ODS1 OPRM1
2 morphine dependence 31.1 OPRD1 OPRK1 OPRM1
3 opioid addiction 30.4 DRD2 OPRD1 OPRK1 OPRM1
4 heroin dependence 30.2 DRD2 OPRD1 OPRM1 PDYN
5 personality disorder 29.4 DRD2 DRD3 SLC6A4 TPH1
6 schizophrenia 28.7 CREB1 DRD2 DRD3 SLC6A4 TH TPH1
7 disease of mental health 28.1 DRD2 DRD3 OPRM1 PDYN POMC SLC6A4
8 alcohol dependence 26.9 DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
9 obsessive-compulsive personality disorder 10.5 DRD3 SLC6A4
10 acidophil adenoma 10.4 IGF1 POMC
11 pituitary infarct 10.4 IGF1 POMC
12 sick building syndrome 10.3 POMC VEGFA
13 sheehan syndrome 10.3 IGF1 POMC
14 mental depression 10.3 POMC SLC6A4 TPH1
15 cerebral hypoxia 10.3 CREB1 IGF1
16 bulimia nervosa 2 10.2 IGF1 POMC SLC6A4
17 chronic fatigue syndrome 10.2 IGF1 POMC SLC6A4
18 panic disorder 10.2 POMC SLC6A4 TPH1
19 hyperpituitarism 10.2 IGF1 POMC
20 central nervous system disease 10.2 NGF SLC6A4 TH
21 west syndrome 10.2 POMC TH TPH1
22 pituitary tumors 10.2 IGF1 POMC VEGFA
23 retrograde amnesia 10.2 PDYN POMC SLC6A4
24 nervous system disease 10.2 NGF TH VEGFA
25 hypothyroidism, congenital, nongoitrous, 4 10.1 IGF1 POMC
26 melanoma metastasis 10.1 CREB1 VEGFA
27 aging 10.1
28 amnestic disorder 10.1 CREB1 PDYN POMC
29 phobic disorder 10.1 OPRK1 SLC6A4
30 somatoform disorder 10.1 NGF OPRM1 TPH1
31 pheochromocytoma 10.1 CREB1 NGF POMC TH
32 alcohol use disorder 10.1 DRD2 SLC6A4
33 episodic pain syndrome, familial, 1 10.1
34 alcohol-induced mental disorder 10.0 DRD2 SLC6A4
35 polysubstance abuse 10.0 DRD2 DRD3
36 tardive dyskinesia 10.0 DRD2 DRD3
37 withdrawal disorder 10.0 OPRM1 PDYN POMC
38 galactorrhea 10.0 DRD2 IGF1
39 impulse control disorder 10.0 DRD2 DRD3
40 alcoholic psychosis 10.0 DRD2 SLC6A4
41 prolactin producing pituitary tumor 10.0 DRD2 NGF
42 pathological gambling 10.0 DRD2 DRD3 SLC6A4
43 migraine without aura 10.0 DRD2 DRD3 SLC6A4
44 hepatitis 9.9
45 neuronitis 9.9
46 delusional disorder 9.9 DRD2 DRD3 TH
47 social phobia 9.9 DRD2 SLC6A4
48 substance abuse 9.9 DRD2 DRD3 SLC6A4
49 alcohol abuse 9.9 DRD2 DRD3 SLC6A4
50 cutaneous solitary mastocytoma 9.9 PDYN POMC

Graphical network of the top 20 diseases related to Opiate Dependence:



Diseases related to Opiate Dependence

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.29 TH PDYN TPH1 POMC VEGFA SLC6A4
2 homeostasis/metabolism MP:0005376 10.21 TH PDYN TPH1 POMC VEGFA SLC6A4
3 growth/size/body region MP:0005378 10.18 TH PDYN TPH1 POMC VEGFA SLC6A4
4 cardiovascular system MP:0005385 10.16 TH TPH1 POMC VEGFA SLC6A4 IGF1
5 integument MP:0010771 10.1 TH PDYN TPH1 POMC VEGFA SLC6A4
6 endocrine/exocrine gland MP:0005379 10.09 OPRM1 TH POMC VEGFA SLC6A4 OPRK1
7 adipose tissue MP:0005375 10.04 OPRM1 PDYN TPH1 POMC DRD3 IGF1
8 nervous system MP:0003631 9.97 TH PDYN POMC VEGFA SLC6A4 IGF1
9 muscle MP:0005369 9.8 SLC6A4 TPH1 VEGFA IGF1 CREB1 NGF
10 no phenotypic analysis MP:0003012 9.56 OPRM1 TH PDYN POMC VEGFA NGF
11 normal MP:0002873 9.23 OPRM1 TH VEGFA SLC6A4 IGF1 CREB1

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 324)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 644073 40400
2
Heroin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 561-27-3 5462328
3
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
4
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-99-3 4095
5
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
6
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 16590-41-3 5360515
7
Nicotine Approved Phase 4,Phase 3,Phase 1,Phase 2 54-11-5 89594 942
8
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
9
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-36-2 446220 5760
10
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-61-6, 62-31-7 681
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 437-38-7 3345
12
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
13
Ribavirin Approved Phase 4,Phase 3,Not Applicable 36791-04-5 37542
14
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2 6740-88-1 3821
15
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
16
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
17
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 5311068 56032 68602
18
Lidocaine Approved, Vet_approved Phase 4,Phase 3 137-58-6 3676
19
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 76-42-6 5284603
20
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
22
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
23
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 60142-96-3 3446
24
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2 56-12-2 119
25
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
26
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 38396-39-3, 2180-92-9 2474
27
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
28
Acetazolamide Approved, Vet_approved Phase 4,Phase 2 59-66-5 1986
29
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
30
Menthol Approved Phase 4 2216-51-5 16666
31
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
32
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
33 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
34 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1
49 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
50 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 584)

# Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
4 Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice Completed NCT00007527 Phase 4 naloxone;buprenorphine
5 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
6 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
7 Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
8 Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
9 Integrating Buprenorphine Into the SFGH AIDS Program Completed NCT00263458 Phase 4
10 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
11 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
12 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
13 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
14 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
15 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
16 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
17 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
18 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
19 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
20 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
21 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
22 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
23 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
24 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
25 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
26 Desvenlafaxine in Opioid-Dependent Patients Completed NCT02200406 Phase 4 Desvenlafaxine
27 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
28 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
29 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
30 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
31 The Maternal Lifestyle Study (MLS) Completed NCT00059540 Phase 4
32 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4 Naltrexone
33 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
34 Feasibility Study of Take-Home LAAM Medication - 3 Completed NCT00000300 Phase 4 LAAM
35 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
36 A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery Completed NCT01374763 Phase 4 Oxycodone;Prolonged-release oxycodone/naloxone
37 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
38 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
39 Effects of Buspirone in Opiate Withdrawal Completed NCT00326235 Phase 4 Buspirone
40 A Stepwise Strategy Utilizing Buprenorphine and Methadone Completed NCT00310934 Phase 4 methadone;buprenorphine / methadone sequence
41 A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic Recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
42 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Recruiting NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
43 Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
44 Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain Recruiting NCT02741076 Phase 4 Morphine Sulfate ER;Oxycodone ER;Oxymorphone ER
45 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
46 Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia Recruiting NCT02992938 Phase 4 Acetazolamide;Placebo Oral Tablet
47 Biomarkers of Injectable Extended Release Naltrexone Treatment Active, not recruiting NCT02324725 Phase 4 Naltrexone
48 Extended Release Naltrexone for Opioid-Dependent Youth Active, not recruiting NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
49 Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings Enrolling by invitation NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
50 Liposomal Bupivacaine in Ambulatory Hand Surgery Enrolling by invitation NCT02933814 Phase 4 Liposomal Bupivicaine

Search NIH Clinical Center for Opiate Dependence

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: opioid-related disorders

Genetic Tests for Opiate Dependence

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

38
Testes, Brain, Skin, Bone, Breast, Liver, Prefrontal Cortex

Publications for Opiate Dependence

Articles related to Opiate Dependence:

(show top 50) (show all 246)
# Title Authors Year
1
Opiate dependence induces cell type-specific plasticity of intrinsic membrane properties in the rat juxtacapsular bed nucleus of stria terminalis (jcBNST). ( 28986608 )
2017
2
Regional cerebral blood flow in opiate dependence relates to substance use and neuropsychological performance. ( 28627790 )
2017
3
Breastfeeding support and opiate dependence: A think aloud study. ( 28494389 )
2017
4
Influence of Psychiatric and Personality Disorders on Smoking Cessation Among Individuals in Opiate Dependence Treatment. ( 27064523 )
2016
5
A thalamic input to the nucleus accumbens mediates opiate dependence. ( 26840481 )
2016
6
TPH1 and 5-HTTLPR Genes Specifically Interact in Opiate Dependence but Not in Alcohol Dependence. ( 27045756 )
2016
7
Buprenorphine Maintenance Treatment of Opiate Dependence: Correlations Between Prescriber Beliefs and Practices. ( 26771870 )
2016
8
A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study). ( 26753792 )
2016
9
Measuring Health and Broader Well-Being Benefits in the Context of Opiate Dependence: The Psychometric Performance of the ICECAP-A and the EQ-5D-5L. ( 27712710 )
2016
10
An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. ( 26990598 )
2016
11
Frontal Metabolite Concentration Deficits in Opiate Dependence Relate to Substance Use, Cognition, and Self-Regulation. ( 27695638 )
2016
12
Nonopiate Methods for Treatment of Opiate Dependence. ( 29368475 )
2016
13
Interim Buprenorphine Treatment in Opiate Dependence: A Pilot Effectiveness Study. ( 26176490 )
2015
14
Role of Temperament, Personality Traits and Onset Age of Smoking in Predicting Opiate Dependence. ( 26870712 )
2015
15
Retention in Medication-Assisted Treatment for Opiate Dependence: A Systematic Review. ( 26467975 )
2015
16
Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence. ( 26711857 )
2015
17
Analysis of connectivity in NeuCube spiking neural network models trained on EEG data for the understanding of functional changes in the brain: A case study on opiate dependence treatment. ( 26000776 )
2015
18
Opiate dependence in schizophrenia: case presentation and literature review. ( 25392062 )
2014
19
Buprenorphine for opiate dependence: clinic based therapy in Israel. ( 25841225 )
2014
20
Take home maintenance medication in opiate dependence. ( 23837085 )
2013
21
Enlarged cavum septum pellucidum as a neurodevelopmental marker in adolescent-onset opiate dependence. ( 24205275 )
2013
22
Elevated IGF1 in clinical opiate dependence. ( 23524620 )
2013
23
Exercise as an adjuvant intervention in opiate dependence. ( 23577897 )
2013
24
Effects of opiate dependence through different administration routes on pulmonary inflammation and its severity. ( 24693370 )
2013
25
Manifold implications of forgotten hyperglycemia in clinical opiate dependence. ( 22313373 )
2013
26
Receipt of prescribed controlled substances by adolescents and young adults prior to presenting for opiate dependence treatment. ( 24826367 )
2013
27
Association between DRD2, 5-HTTLPR, and ALDH2 genes and specific personality traits in alcohol- and opiate-dependent patients. ( 23685324 )
2013
28
Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared. ( 22703715 )
2013
29
Duration of opiate exposure as a determinant of arterial stiffness and vascular age in male opiate dependence: a longitudinal study. ( 24329809 )
2013
30
Social stress engages opioid regulation of locus coeruleus norepinephrine neurons and induces a state of cellular and physical opiate dependence. ( 23660707 )
2013
31
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. ( 23624062 )
2013
32
Medication-assisted treatment of opiate dependence is gaining favor. ( 23733899 )
2013
33
Opiate dependence as an independent and interactive risk factor for arterial stiffness and cardiovascular ageing - a longitudinal study in females. ( 23976908 )
2013
34
Opiate dependence induces network state shifts in the limbic system. ( 23911767 )
2013
35
Premature ejaculation and other sexual dysfunctions in opiate dependent men receiving methadone substitution treatment. ( 21920671 )
2012
36
KPNA3 variation is associated with schizophrenia, major depression, opiate dependence and alcohol dependence. ( 22960338 )
2012
37
Association of nerve growth factor and vascular endothelial growth factor A with psychometric measurements of opiate dependence: results of a pilot study in patients participating in a structured diamorphine maintenance program. ( 22517242 )
2012
38
Differing age related trajectories of dysfunction in several organ systems in opiate dependence. ( 21339699 )
2012
39
Effect of craving induction on inhibitory control in opiate dependence. ( 21952672 )
2012
40
Relative and age-dependent stimulation of soluble and cellular immunity in opiate dependence. ( 21918466 )
2012
41
Alpha-synuclein and heroin craving in opiate-dependent patients on injectable heroin maintenance. ( 21309955 )
2012
42
Ecological momentary assessment in alcohol, tobacco, cannabis and opiate dependence: a comparison of feasibility and validity. ( 22647899 )
2012
43
Pharmacological treatments of opiate dependence. ( 21524267 )
2011
44
The effect of pain on stroop performance in patients with opiate dependence in sustained remission. ( 21769047 )
2011
45
Functional imaging of emotion reactivity in opiate-dependent borderline personality disorder. ( 22448769 )
2011
46
Serum levels of BDNF are associated with craving in opiate-dependent patients. ( 21890593 )
2011
47
Deterioration of indices of aortic augmentation and vascular age predate major cardiac events and interact with opiate dependence. ( 19327850 )
2011
48
Differences between men and women in the course of opiate dependence: is there a telescoping effect? ( 19838765 )
2010
49
Association between Novelty Seeking of opiate-dependent patients and the catechol-O-methyltransferase Val(158)Met polymorphism. ( 20728009 )
2010
50
Buprenorphine in the treatment of opiate dependence. ( 20648912 )
2010

Variations for Opiate Dependence

Expression for Opiate Dependence

Search GEO for disease gene expression data for Opiate Dependence.

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 CREB1 DRD2 DRD3 IGF1 NGF OPRD1
2
Show member pathways
13.31 DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
3
Show member pathways
12.3 CREB1 IGF1 OPRM1 VEGFA
4
Show member pathways
12.26 CREB1 OPRM1 PDYN POMC
5 12.17 CREB1 NGF OPRM1 POMC TH TPH1
7
Show member pathways
11.74 CREB1 DRD2 PDYN TH
8 11.68 OPRD1 OPRM1 POMC VEGFA
9
Show member pathways
11.62 DRD2 DRD3 TH
10 11.46 IGF1 NGF TH VEGFA
11 11.31 CREB1 NGF SLC6A4 TH TPH1 VEGFA
12
Show member pathways
10.88 TH TPH1
13 10.87 DRD2 DRD3
14 10.81 CREB1 TH

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.65 DRD2 OPRK1 OPRM1 PDYN TH
2 axon GO:0030424 9.62 CREB1 DRD2 OPRM1 TH
3 perikaryon GO:0043204 9.46 DRD2 OPRK1 OPRM1 TH
4 dendrite membrane GO:0032590 9.37 OPRD1 OPRM1
5 axon terminus GO:0043679 9.26 DRD2 OPRD1 OPRK1 PDYN
6 neuron projection GO:0043005 9.1 OPRD1 OPRK1 OPRM1 SLC6A4 TH TPH1

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.97 OPRD1 OPRK1 OPRM1 PDYN
2 response to drug GO:0042493 9.96 CREB1 DRD2 DRD3 SLC6A4 TH
3 circadian rhythm GO:0007623 9.85 CREB1 SLC6A4 TPH1
4 memory GO:0007613 9.83 CREB1 SLC6A4 TH
5 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.83 OPRD1 OPRK1 OPRM1
6 response to hypoxia GO:0001666 9.83 CREB1 DRD2 SLC6A4 TH VEGFA
7 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.82 OPRD1 OPRK1 OPRM1
8 sensory perception of pain GO:0019233 9.81 OPRD1 OPRK1 OPRM1
9 cellular response to growth factor stimulus GO:0071363 9.8 CREB1 OPRD1 TH
10 social behavior GO:0035176 9.79 DRD3 SLC6A4 TH
11 visual learning GO:0008542 9.79 CREB1 DRD2 DRD3
12 response to nicotine GO:0035094 9.77 CREB1 DRD2 TH
13 negative regulation of adenylate cyclase activity GO:0007194 9.74 DRD2 DRD3 OPRM1
14 positive regulation of receptor internalization GO:0002092 9.72 DRD2 VEGFA
15 regulation of dopamine secretion GO:0014059 9.72 DRD2 DRD3
16 dopamine receptor signaling pathway GO:0007212 9.72 DRD2 DRD3
17 positive regulation of neuroblast proliferation GO:0002052 9.72 DRD2 VEGFA
18 regulation of sensory perception of pain GO:0051930 9.72 OPRD1 OPRK1 OPRM1
19 response to ethanol GO:0045471 9.72 DRD2 DRD3 OPRK1 OPRM1 TH
20 positive regulation of Ras protein signal transduction GO:0046579 9.71 IGF1 NGF
21 mammary gland alveolus development GO:0060749 9.71 TPH1 VEGFA
22 eye photoreceptor cell development GO:0042462 9.71 TH VEGFA
23 negative regulation of protein secretion GO:0050709 9.71 DRD2 DRD3
24 response to growth factor GO:0070848 9.71 OPRM1 TH
25 positive regulation of CREB transcription factor activity GO:0032793 9.7 OPRD1 VEGFA
26 positive regulation of long-term synaptic potentiation GO:1900273 9.7 CREB1 DRD2
27 estrous cycle GO:0044849 9.7 OPRK1 OPRM1
28 behavioral response to ethanol GO:0048149 9.7 DRD2 OPRM1
29 dopamine metabolic process GO:0042417 9.69 DRD2 DRD3
30 neurotransmitter biosynthetic process GO:0042136 9.69 SLC6A4 TH
31 prepulse inhibition GO:0060134 9.69 DRD2 DRD3
32 response to amphetamine GO:0001975 9.69 DRD2 DRD3 TH
33 positive regulation of renal sodium excretion GO:0035815 9.68 DRD2 DRD3
34 G-protein coupled receptor internalization GO:0002031 9.68 DRD2 DRD3
35 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.67 DRD2 DRD3
36 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.67 DRD3 OPRM1
37 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD3 OPRK1
38 response to cocaine GO:0042220 9.67 DRD2 DRD3 OPRK1 OPRM1
39 aromatic amino acid family metabolic process GO:0009072 9.66 TH TPH1
40 regulation of cAMP metabolic process GO:0030814 9.65 DRD2 DRD3
41 synaptic transmission, dopaminergic GO:0001963 9.65 DRD2 DRD3 TH
42 neuropeptide signaling pathway GO:0007218 9.65 OPRD1 OPRK1 OPRM1 PDYN POMC
43 sensory perception GO:0007600 9.63 OPRK1 OPRM1 PDYN
44 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.62 DRD2 DRD3
45 negative regulation of dopamine receptor signaling pathway GO:0060160 9.59 DRD2 DRD3
46 acid secretion GO:0046717 9.58 DRD2 DRD3
47 response to histamine GO:0034776 9.58 DRD2 DRD3
48 opioid receptor signaling pathway GO:0038003 9.58 OPRD1 OPRK1 OPRM1
49 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.54 OPRK1 OPRM1
50 regulation of locomotion involved in locomotory behavior GO:0090325 9.52 DRD2 DRD3

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD2 DRD3
2 neuropeptide binding GO:0042923 9.33 OPRD1 OPRK1 OPRM1
3 dopamine neurotransmitter receptor activity GO:0004952 9.32 DRD2 DRD3
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.26 TH TPH1
5 dopamine binding GO:0035240 9.13 DRD2 DRD3 TH
6 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Opiate Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....